Psyence and Filament Health have announced the conclusion of an exclusive licensing agreement. Under the terms of the agreement, Filament will license its proprietary botanical drug candidate PEX010 (25mg) and the associated IP to Psyence for use in Psyence’s upcoming clinical trials.
Category Press Release
Published in GlobeNewswire
Companies Featured
Filament HealthFilament Health is a global extraction and drug discovery company. The company have a deep natural psychedelics IP portfolio and are led by an accomplished botanical extraction management team.
Psyence Group
Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.